Related by context. All words. (Click for frequent words.) 67 Panzem R NCD 67 Phase 2b Clinical Trial 66 Alocrest 66 Meets Primary Endpoint 66 GAMMAGARD 65 phase IIa clinical 65 Archexin 65 reslizumab 65 Aflibercept 65 IMA# 64 OvaRex R 64 YONDELIS 64 R#/MEM # 64 Panzem R 64 Chemophase 64 TLK# 64 tezampanel NGX# 64 Phase 1a clinical 64 APEX PD 64 ZFP Therapeutics 64 Allovectin 7 64 Mipomersen 64 Phase #b/#a clinical 64 Glufosfamide 64 PF # [002] 63 XL# XL# XL# XL# 63 Exherin 63 Plicera 63 acyclovir Lauriad R 63 Factor VIIa 63 Inhalation Solution 63 Ceflatonin R 63 Phase Ib study 63 PDE4 inhibitor 63 intranasal formulation 63 elotuzumab 63 SinuNase TM 63 Phase 2b clinical trials 63 Phase III Clinical Trial 63 Xanafide 63 KNS # 63 oral prodrug 63 PANVAC VF 63 GALNS 63 Surfaxin LS 63 ularitide 63 Phase IIb Trial 63 Iluvien TM 63 pertuzumab 63 BENLYSTA ® 63 Daclizumab 63 INCB# [001] 63 orally administered inhibitor 63 CD# CEA 63 GVAX ® 63 Dyloject TM 63 Anturol TM 62 targeted radiotherapeutic 62 oral picoplatin 62 Solazed TM 62 Urocortin 2 62 oncolytic virus therapies 62 Zemplar Capsules 62 evaluating tivozanib 62 Phase IIa trials 62 HuMax EGFr 62 vinorelbine tartrate 62 mGluR2 positive 62 Cloretazine ® 62 Aryplase 62 docetaxel Taxotere ® 62 Traficet EN 62 tiapamil 62 tanespimycin 62 OvaRex 62 AzaSite Plus 62 PRT# 62 Phase 2b Trial 62 Initiate Clinical Trial 62 Romidepsin 62 MKC# MT 62 Successfully Completes Phase 62 KRN# 62 celgosivir 62 LibiGel ® 62 orBec 62 Ixabepilone 62 Elotuzumab 62 Ophena TM 62 THR beta agonist 61 novel VDA molecule 61 hyaluronidase enzyme 61 Phase 2b Study 61 fostamatinib 61 Immunotherapeutic 61 BrachySil TM 61 catheter occlusion 61 TRO# 61 RhuDex ® 61 phase IIa 61 liposomal formulation 61 metaglidasen 61 aldehyde dehydrogenase ALDH2 deficiency 61 First Patient Dosed 61 Phase 1b trial 61 Phase III Trial 61 ASONEP 61 pharmacokinetic PK study 61 TKB# 61 Pafuramidine 61 CRLX# 61 miconazole Lauriad ® 61 CoFactor 61 LUMINATE 61 molecular imaging radiopharmaceutical 61 alvespimycin 61 HuMax CD4 61 GW# [003] 61 Pivotal Phase 61 Clolar ® 61 TBC# 61 Aclidinium 61 DAVANAT 61 Phase IIb clinical trials 61 OncoGel 61 XL# anticancer compounds 61 FOLFOX6 chemotherapy regimen 61 LymphoStat B belimumab 61 lintuzumab SGN 61 AZILECT R 61 TMC# [002] 61 CRMD# 61 lumiliximab 61 MKC# 61 Phase Ib clinical 61 UPLYSO 61 selective androgen receptor modulator 61 Phase 2a clinical trials 61 Aerosurf 61 Initiate Phase II 61 forodesine hydrochloride 61 dacetuzumab 61 galiximab 61 mertansine 61 Vandetanib 61 Zemiva ™ 61 octreotide acetate 61 HCD# [002] 61 Completes Patient Enrollment 61 Relovair 61 PRTX 61 CIMZIA TM 61 XL# XL# 61 JAK2 inhibitor 61 Liposomal 61 Phase IIb trials 61 Testosterone MDTS ® 60 alemtuzumab Campath 60 HDAC Inhibitor 60 RhuDex 60 Trofex 60 seliciclib CYC# 60 tubulin inhibitor 60 Exelixis compounds 60 Pivotal Phase III 60 Capesaris 60 Panzem NCD 60 NPC 1C 60 R#/MEM 60 metastatic malignant 60 refractory chronic lymphocytic 60 Pazopanib 60 Files Investigational 60 SNT MC# 60 Initiates Clinical 60 Vascular Disrupting Agent 60 TOCOSOL Paclitaxel 60 rALLy 60 Initiate Phase 60 Oral Spray 60 Phase Ib Clinical Trial 60 Clonicel 60 inhaled AAT 60 BEMA TM Fentanyl 60 NGX# 60 oral proteasome inhibitor 60 docetaxel Taxotere R 60 ALN TTR 60 Phase IIb Clinical Trial 60 Pivotal Phase II 60 tezampanel 60 OMNARIS Nasal Spray 60 PEGylated interferon 60 Amigal 60 Phase 1b Clinical Trial 60 urocortin 2 60 eprotirome 60 Onalta ™ 60 CYT# potent vascular disrupting 60 Spiegelmer ® 60 oral taxane 60 DUROS 60 Vilazodone 60 Icatibant 60 Phase 2a Clinical Trial 60 Medoxomil 60 PNP inhibitor 60 telaprevir VX 60 Pemetrexed 60 CCX# 60 fosbretabulin 60 Proellex TM 60 Golimumab 60 ospemifene 60 ZEVALIN ® 60 Aeroquin 60 omiganan 60 IRX 2 60 Elagolix 60 vaccines oncolytic virus 60 Xeloda ® 60 trastuzumab DM1 T DM1 60 BEMA Buprenorphine 60 HGS# 60 ACTEMRA TM 60 Novolimus 60 INTEGRILIN R eptifibatide Injection 60 teriflunomide 60 Phenoptin 60 Bezielle 60 budesonide foam 60 deforolimus 60 cathepsin K inhibitor 60 Acetavance TM intravenous acetaminophen 60 Initiates Phase II 60 Hsp# Inhibitor 60 Insegia 60 Achieves Primary Endpoint 60 Melphalan 60 Xyfid TM 60 severe hypercholesterolemia 60 G#DT 60 Pivotal Trial 60 Initiates Phase III 60 PEG IFN 60 Ocrelizumab 60 Pimavanserin 60 Medidur TM FA 60 Initiated Phase 60 MKC# MKC# PP 60 Phase III Trials 60 Silodosin 60 Androxal TM 59 photoprotective drug 59 novel oral anticoagulant 59 HuMax 59 initiated Phase 1b 59 baminercept 59 Aurora kinase inhibitor 59 Vivecon 59 Kosan dependence 59 IL# PE#QQR 59 Perforomist ™ Inhalation Solution 59 DPX Survivac 59 Zenvia ™ 59 Evoltra 59 Sapacitabine 59 AAG geldanamycin analog 59 Vitaxin 59 ADP receptor antagonist 59 Xcellerated T Cells 59 riociguat 59 Firazyr 59 Phase Ib II 59 ONCONASE R 59 Aplidin 59 PREOS R 59 pradefovir 59 metastatic hormone refractory 59 OncoVEX GM CSF 59 Phase III Pivotal 59 somatostatin analogue 59 CEQ# 59 Cetuximab Erbitux 59 Oral NKTR 59 Troxatyl 59 oral ridaforolimus 59 Locteron ® 59 JAK inhibitor 59 BCX# 59 Fx #A 59 EP #R 59 PrevOnco 59 CCX# B 59 ALN HPN 59 E1 INT TM 59 omacetaxine mepesuccinate 59 torezolid phosphate 59 vemurafenib 59 Tesetaxel 59 HuMax CD# 59 Phase Ib clinical trials 59 Phase 1b clinical trials 59 Gabapentin GR 59 Personalized Immunotherapy 59 IIa clinical 59 Intravesical 59 XL# XL# XL# 59 MAGE A3 ASCI 59 Phase III registrational 59 StemEx 59 GLP1 INT TM 59 Bicifadine 59 rilonacept 59 forodesine 59 Targeted Chemotherapy 59 bardoxolone 59 Pivotal Trials 59 cetuximab Erbitux ® 59 Zemiva TM 59 AEGR 59 OHR/AVR# 59 DEB# 59 OvaRex ® MAb 59 atrasentan 59 Cloretazine R VNP#M 59 novel nucleoside analog 59 ocrelizumab 59 MGN# 59 TELINTRA R 59 ALN PCS 59 occlusion PAO 59 Myocet 59 registrational trial 59 trastuzumab Herceptin R 59 XmAb# 59 Forodesine 59 BAL# [002] 59 including eniluracil ADH 59 LymphoStat B TM 59 DermaVir Patch 59 SYN# 59 vapreotide acetate 59 GATTEX TM 59 PRN FDA Approves 59 Trial Evaluating 59 SAR# [002] 59 Ramoplanin 59 TG# [001] 59 farletuzumab 59 PSMA ADC 59 canagliflozin 59 Phase Ib IIa 59 BEMA Granisetron 59 PHX# 59 Phase III Clinical Trials 59 Investigational Oral 59 phase IIb trial 59 Anthim 58 Allovectin 7 R 58 anti CD3 monoclonal 58 volociximab 58 ara C 58 Azedra 58 Quinamed 58 Omacetaxine 58 Vicriviroc 58 evaluating picoplatin 58 elacytarabine 58 CR# vcMMAE 58 compound INCB# 58 entinostat 58 TACI Ig 58 Ixempra 58 Proxinium TM 58 GLP toxicology studies 58 Pivotal Study 58 rALLy clinical trial 58 alfa 2a 58 LEVADEX ™ 58 Chimigen TM 58 tramiprosate Alzhemed TM 58 Multiple Ascending Dose 58 tolevamer 58 ganetespib 58 JAK1 58 FOLOTYN ® 58 Cimzia ® certolizumab pegol 58 AeroLEF TM 58 Pharmacokinetics PK 58 bortezomib Velcade R 58 MyVax ® 58 Ketotransdel 58 Bayer HealthCare Onyx Pharmaceuticals 58 RGB # 58 Anturol 58 PDX pralatrexate 58 Phase #/#a 58 Nexavar ® 58 Nanobody 58 Efficacy Trial 58 Tyrima 58 ® natalizumab 58 DDP# 58 Otelixizumab 58 Trofex TM 58 DexaSite 58 Virulizin ® 58 eltrombopag 58 TG# [003] 58 Luveniq 58 Onconase 58 phase IIb clinical 58 opioid induced bowel dysfunction 58 AS# amonafide L malate 58 refractory metastatic 58 receptor tyrosine kinase inhibitor 58 selective adenosine 58 Hyphanox 58 Leukine ® 58 GVAX R 58 Ceflatonin 58 PEG PAL 58 ruxolitinib 58 GSK# [002] 58 cediranib 58 midstage clinical 58 radiation sensitizer 58 stated Michelle Berrey 58 Fibrillex TM 58 dacetuzumab SGN 58 antiangiogenesis therapies 58 cannabinor 58 Ozarelix 58 antibody MAb 58 investigational protease inhibitor 58 NovaBay Aganocide compounds 58 phase IIb 58 isoform selective 58 novel histone deacetylase 58 GRN# 58 cancer immunotherapies 58 TASKi3 58 GVAX Pancreas Vaccine 58 GetGoal 58 palifosfamide Zymafos TM 58 interferon beta therapy 58 PEG Interferon lambda 58 Amplimexon 58 CORT # 58 EGEN 58 CAMPATH 58 histone deacetylase HDAC inhibitor 58 OncoVex 58 albiglutide 58 Gemzar ® 58 Alnylam #x# 58 Trobalt 58 Commences Phase 58 non nucleoside HCV 58 Vicinium TM 58 bortezomib Velcade 58 PNT# 58 Alvesco R 58 Onyx Pharmaceuticals Announces 58 BLP# Liposome Vaccine 58 CBLC# 58 Azedra TM 58 NVA# 58 telomerase therapeutic 58 dextromethorphan quinidine 58 IMC #B 58 Alferon N 58 obatoclax 58 paclitaxel poliglumex 58 ISTODAX ® 58 Dual Opioid 58 AEG# 58 pegylated interferon alpha 2a 58 XP# XP# 58 tiuxetan 58 Enobia 58 Brentuximab Vedotin SGN 58 lesinurad 58 EOquin TM 58 Randomized Phase 58 Phase IIIb 58 Phase III HEAT 58 non nucleoside inhibitor 58 trastuzumab DM1 58 vosaroxin 58 Phase IIB 58 EDEMA3 58 ISIS # 58 ixabepilone 58 Degarelix 58 ThermoDox ® clinical 58 Fludara ® 58 Cloretazine 58 TransMID 58 Urocidin 58 next generation URAT1 58 generation purine nucleoside 58 Metastatic Melanoma 58 HspE7 58 subcutaneous formulation 58 AZILECT ® 58 polymer platinate 58 tenofovir disoproxil fumarate Viread 57 cetuximab Erbitux R 57 midstage trials 57 investigational antiplatelet agent 57 Phase 2a trial 57 ChronVac C R 57 ZOLINZA 57 essential thrombocythemia ET 57 PEGylated Fab fragment 57 CB2 selective receptor agonist 57 ELACYT 57 Intravenous CP 57 Targretin capsules 57 Amrubicin 57 ENDEAVOR IV 57 SEPET TM 57 sorafenib tablets 57 regorafenib 57 LEUKINE 57 BROVANA 57 AMEVIVE 57 Safinamide 57 PS# [001] 57 Rigel R# 57 oral rivaroxaban 57 ALN VSP Phase 57 Combination REOLYSIN R 57 Phase 2a Trial 57 Imprime PGG 57 cancer neuroendocrine tumor 57 alvimopan 57 huN# DM1 57 LymphoStat B 57 Carfilzomib 57 Clevudine 57 PI3K/Akt pathway inhibitor 57 Vidaza ® 57 TransVax ™ 57 GSK# [001] 57 Tarceva TM 57 IIb clinical trial 57 vorinostat 57 romidepsin 57 SCH # 57 targeted antifolate 57 Dacogen injection 57 Civacir 57 CDP# 57 confirmatory pivotal 57 TELINTRA 57 relapsing multiple sclerosis 57 BRAF inhibitor 57 2 methoxyestradiol 57 axitinib 57 BiovaxID TM 57 Aptivus ® 57 Plaque Psoriasis 57 ALVESCO R 57 CD# monoclonal antibody 57 incyclinide 57 BrachySil 57 octreotide implant 57 LCP AtorFen 57 adenosine injection 57 erlotinib Tarceva ® 57 IAP inhibitors 57 PrevOnco ™ 57 potent CYP#A# inhibitors 57 OMNARIS AQ 57 Mitoxantrone 57 nalbuphine ER 57 TMC# C# 57 Onalta 57 Zensana TM 57 Sudhir Agrawal D.Phil 57 SAR# [004] 57 aclidinium 57 AVE# 57 Actilon 57 Exelixis XL# 57 5 HT3 antagonist 57 Circ Pharma 57 severe gastroparesis 57 Study Evaluating 57 MDV# 57 RELOVAIR ™ 57 NP2 Enkephalin 57 rxRNA 57 velafermin 57 bevacizumab Avastin ® 57 Phase IIIb clinical 57 histamine dihydrochloride 57 Preclinical studies suggest 57 Saforis 57 Synavive 57 Trastuzumab DM1 57 Iloperidone 57 huC# DM4 57 docetaxel Taxotere 57 Exherin TM 57 Telatinib 57 Corlux 57 LE DT 57 ponatinib 57 Lenocta TM 57 diabetic neuropathic pain 57 MP4OX 57 6R BH4 57 refractory AML 57 orally dosed 57 Panzem ® 57 alemtuzumab MS 57 sodium thiosulfate STS 57 FDA Approvals 57 neratinib 57 Completes Enrollment 57 BrachySil ™ 57 Plenaxis TM 57 TO AVOID PREGNANCY WHILE 57 dependent kinase inhibitor 57 eosinophilic asthma 57 pemetrexed Alimta 57 phase Ib 57 L BLP# 57 HIV integrase inhibitor 57 carcinoid syndrome 57 Aurexis 57 ATL# [001] 57 multicenter Phase 57 Laquinimod 57 Resten NG 57 NO# [002] 57 TM Drug Eluting 57 #D#C# 57 Levoleucovorin 57 brivaracetam 57 peginesatide 57 valopicitabine 57 Dextofisopam 57 Sym# 57 OMP #R# 57 APTIVUS 57 HCV SPRINT 57 cangrelor 57 Neuvenge 57 EGS# 57 ThermoDox R 57 Tumour Vascular Disrupting Agent 56 GA GCB 56 STRIDE PD 56 otelixizumab 56 Frova ® 56 GATTEX ® 56 Bortezomib 56 PRESEPT 56 balsalazide tablet 56 MoxDuo IR 56 Phase Ib 56 romidepsin novel 56 blinded randomized placebo controlled 56 systemic immunosuppressive drugs 56 Protexia ® 56 Pirfenidone 56 Azedra ™ 56 selective A2A adenosine receptor 56 BNC# 56 initiate Phase IIa 56 BAY #-# 56 Stedivaze 56 EndoTAG 56 OMAPRO 56 MAXY alpha 56 relapsed refractory multiple myeloma 56 Diamyd ® 56 Dapagliflozin 56 Darusentan 56 TASKi2 56 initiated Phase Ib 56 ARRY # 56 Genasense ® oblimersen 56 Phase 2a Study 56 Phase 2b study 56 ALN VSP 56 Oral Insulin 56 VISICOL R 56 MEK Inhibitor 56 lintuzumab 56 Phase IIa trial 56 NEUMUNE 56 Allovectin 7 r 56 MAP# 56 TRAIL receptor antibodies 56 Zerenex 56 JZP 56 miconazole Lauriad R 56 Pharmacokinetic Study 56 TKM PLK1 56 Dose Escalation 56 ALVESCO ® 56 dexanabinol 56 Fodosine 56 OncoVEX 56 HEPLISAV ™ 56 Clinical Trial Results 56 OSMOPREP 56 maximally tolerated dose 56 LEP ETU 56 Viprinex TM 56 Aptocine 56 leading oral taxane 56 Pharmos pipeline 56 evaluating mipomersen 56 bendamustine 56 CCR5 mAb 56 Phase 2b monotherapy 56 topical gel formulation 56 assessing T DM1 56 Curaxin CBLC# 56 efficacy endpoint 56 recurrent metastatic ovarian cancer 56 Intarcia 56 Vinorelbine 56 Intraject 56 includes TOLAMBA TM 56 mapatumumab 56 RE COVER 56 custirsen 56 elagolix 56 CVac 56 Omnitarg 56 LAF# 56 Allovectin 7 ® 56 Diabetic Neuropathy 56 Zenvia TM 56 trospium 56 lomitapide 56 Genz # 56 Sandostatin LAR Depot 56 S1P antibody 56 Dabigatran etexilate 56 EndoTAG TM -1 56 Bioral Amphotericin B 56 ATryn R 56 confirmatory Phase III 56 GOUT 56 Onrigin 56 Telaprevir 56 EDEMA3 trial 56 Cintredekin Besudotox 56 Asentar 56 CorVue ™ 56 Phase 1b 56 BRIM2 56 relapsed multiple myeloma 56 mGluR5 negative 56 MGd 56 TAFA# 56 Alzhemed TM 56 talactoferrin 56 Orazol 56 Endeavor DES 56 ribavirin Copegus ® 56 Loramyc R 56 selective immunoproteasome inhibitor 56 Benlysta belimumab 56 Randomized Double blind 56 Phase #/#a trial 56 Second Pivotal Phase 56 GLPG# 56 MabThera rituximab 56 subcutaneously administered 56 small molecule tyrosine 56 sapacitabine CYC# 56 Confirmatory Phase 56 Transdermal Delivery 56 unique alkylating agent 56 Phase 2a clinical 56 prokinetic agent 56 Tanespimycin 56 Prodarsan 56 Viprinex 56 phase Ib clinical 56 aflibercept 56 randomized controlled Phase 56 Perifosine 56 lapatinib Tykerb 56 TYKERB 56 MT# MEDI 56 Paromomycin 56 Celgosivir 56 EXPLORE Xa 56 thymalfasin 56 Annamycin 56 StemEx R 56 OMP #M# 56 INCB# [003] 56 CD3 monoclonal antibody 56 VEGFR2 inhibitor 56 Efficacy Results 56 NOX E# 56 HGS ETR2 56 rNAPc2 56 Initiates Clinical Trials 56 Triolex 56 Phase III multicenter 56 ofatumumab HuMax CD# 56 evaluating satraplatin 56 pioglitazone HCl 56 PLK1 SNALP 56 CTA# Injection 56 non nucleoside 56 developing Bicifadine serotonin 56 eritoran 56 serum uric acid sUA 56 IIa clinical trials 56 PFO migraine 56 MEND CABG 56 abiraterone acetate 56 Cetrorelix 56 acute peripheral arterial 55 Dose Ranging Study 55 inhalation powder 55 PREOS 55 AIMM trial 55 sunitinib malate 55 vidofludimus 55 GLP1 agonist 55 Selective Electrochemical Tumor Ablation 55 gemtuzumab ozogamicin 55 StaphVAX 55 rALLy trial 55 ISTODAX 55 Alequel ™ 55 zileuton 55 RNAi Therapeutic 55 Ambrisentan 55 QVAR 55 oral treprostinil 55 synthetic retinoid 55 Sumatriptan Succinate 55 Myoblast 55 multicenter Phase III 55 TASQ 55 Dacogen decitabine 55 adecatumumab MT# 55 PEG SN# 55 Cleviprex TM clevidipine 55 avanafil 55 IB# [002] 55 Litx 55 ORE# 55 brand ciclesonide HFA 55 phase IIb study 55 drug pipeline TAFA# 55 ongoing Phase 1b 55 Phase 1b clinical 55 sorafenib Nexavar ® 55 lead Aganocide compound 55 Zenvia Phase III 55 Orally administered 55 Oglemilast 55 HGS ETR1 mapatumumab 55 aflibercept VEGF Trap 55 Phase #b/#a trial 55 ILUVIEN ® 55 TroVax 55 ENMD # 55 anticancer compound 55 HepeX B TM 55 ACUROX ® 55 RH1 55 ORENCIA ® 55 cutaneous T 55 MEND CABG II 55 Glybera R 55 Rezular 55 orally inhaled 55 EFAPROXYN 55 refractory cutaneous T 55 Initiates Phase 55 TNFerade TM 55 bevacizumab Avastin R 55 ADVANCE PD 55 commercialize deforolimus 55 LBH# 55 RITUXAN 55 Abiraterone acetate 55 pralatrexate injection folate analogue 55 Pralatrexate 55 Clinical Trial Evaluating 55 DR Cysteamine 55 Kahalalide F 55 paclitaxel Taxol ® 55 immunotherapeutic agent 55 dimebon 55 INC# 55 Huntexil 55 CA4P 55 Nascobal Nasal Spray 55 Tasimelteon 55 LUVENIQ 55 GV# [001] 55 visilizumab 55 budesonide MMX 55 Reverset 55 1mg 2mg 55 Ecallantide 55 omega interferon 55 velaglucerase alfa 55 mitogen activated ERK kinase 55 HepaSphere 55 ANYARA 55 MGCD# [001] 55 Adult Stem Cell Therapy 55 Randomised 55 Prostate AdenoCarcinoma Treatment 55 Phase 2a 55 Tyrosine Kinase Inhibitor 55 methylnaltrexone 55 opioid bowel dysfunction 55 hormone LHRH antagonist 55 Phase III confirmatory 55 Phase IIa 55 EmbraceAC 55 Avicena 55 advanced carcinoid 55 modified glutathione analog 55 eTag assays 55 sterile lidocaine patch 55 Intravenous Human 55 ® pramlintide acetate 55 lorvotuzumab mertansine 55 IIa trial 55 Drug Eluting Stent System 55 Harry Palmin President 55 personalized immunotherapy 55 multicentre randomized 55 olaparib 55 ASA# 55 GTC recombinant human 55 trodusquemine 55 PHASE III 55 Kamada AAT 55 ProLindac 55 multicenter placebo controlled 55 MEK inhibitor 55 PF # [001] 55 Phase III TRIST 55 Jevtana 55 Carbidopa 55 zanolimumab 55 EOquin 55 Phase III 55 dose escalation clinical 55 iniparib 55 adjuvant GIST 55 enzastaurin 55 PROMACTA ® 55 agonistic human 55 AFREZZA TM 55 Symadex 55 QTinno TM 55 ZACTIMA 55 IND enabling 55 confirmatory clinical 55 Poly ICR 55 candidates Dyloject TM 55 ALN TTR# 55 estrogen receptor antagonist 55 Demonstrates Potential 55 Methylnaltrexone 55 patented Bioral 55 terlipressin 55 AVN# [001] 55 Locteron 55 initiate Phase 2b 55 ToGA 55 Thorough QT 55 BLA filing 55 Tarvacin TM 55 ATPace TM 55 Sulonex TM 55 Etubics 55 #mg dose [002] 55 Protease Inhibitor 55 tumor vascular disrupting 55 gemcitabine cisplatin 55 cetuximab Erbitux 55 favorable pharmacokinetic profile 55 class mGluR5 inhibitor 55 LB# [003]